AriBio’s split Phase III result reflects a mixed CTAD
Will FDA want another AriBio trial? Plus, a tau biomarker puzzle and a third amyloid oligomer miss
A step change in benefit for Alzheimer’s patients remained elusive at this year’s CTAD conference. AriBio delivered a rare Phase III win in the disease, though its oral therapy AR1001 showed a statistically significant benefit only among patients who entered the trial off symptomatic medication. That split result captured a mixed CTAD, where a failed tau antibody trial offered a lesson in interpreting biomarkers, and a third therapy targeting amyloid oligomers missed its primary efficacy endpoint.
In a separate clinical update, Biogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported a widening advantage for low-dose diranersen, a tau-lowering antisense oligo, on five of six clinical measures between weeks 76 and 96. The later comparison with patients originally assigned to placebo came during the open-label extension of Phase II CELIA, which had missed its primary dose-response endpoint at week 76. The lowest dose again showed the largest numerical benefit, reinforcing the question of how much tau lowering p...

